TL;DR: Aetna, a CVS Health company, modified CPB 0377 covering dendritic cell immunotherapy, effective September 26, 2025. Here's what billing teams need to do.
Aetna's dendritic cell immunotherapy coverage policy under CPB 0377 Aetna system covers a broad range of malignant neoplasm diagnoses — from leukemia and lymphoma to melanoma and solid tumors — mapped to ICD-10-CM codes spanning C00.0 through C96.9, plus melanoma in situ codes D03.0 through D03.9. This modification went live September 26, 2025. If your practice treats oncology patients with Aetna coverage, this is the policy governing whether dendritic cell immunotherapy billing gets paid or denied.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Dendritic Cell Immunotherapy |
| Policy Code | CPB 0377 |
| Change Type | Modified |
| Effective Date | 2025-09-26 |
| Impact Level | High |
| Specialties Affected | Oncology, Hematology, Dermatology, Surgical Oncology |
| Key Action | Audit all open Aetna claims and pending prior authorizations for dendritic cell immunotherapy against the updated ICD-10-CM diagnosis code set before submitting new claims |
Aetna Dendritic Cell Immunotherapy Coverage Criteria and Medical Necessity Requirements 2025
The Aetna dendritic cell immunotherapy coverage policy under CPB 0377 is built around diagnosis — not just procedure. Medical necessity for dendritic cell immunotherapy ties directly to a covered malignant neoplasm diagnosis. Your ICD-10-CM coding on the claim has to match the covered diagnosis ranges, or you're looking at a claim denial on the front end.
The covered diagnosis set is wide. It runs from C00.0 (malignant neoplasm of the external upper lip) through C96.9 (hematologic malignancy, unspecified), plus melanoma in situ codes D03.0 through D03.9. That covers leukemia, lymphoma, melanoma, and solid tumors. Essentially, the full spectrum of malignancies is in scope.
Medical necessity documentation needs to support the specific cancer diagnosis. "Malignant neoplasm" on a claim without a precise ICD-10-CM code from the covered ranges won't hold up under audit. Be specific — if your patient has diffuse large B-cell lymphoma, code it precisely rather than defaulting to a catch-all malignancy code.
Prior authorization requirements for dendritic cell immunotherapy under Aetna should be confirmed at the plan level before scheduling treatment. CPB 0377 governs coverage policy broadly, but individual Aetna plans vary on prior auth requirements. Call to verify before the patient starts treatment — not after.
One thing billing teams should know: the covered diagnosis codes skipping over certain C-code ranges isn't a typo. The ranges C43.9 through C44.00, C75.9 through C76.0, C86.61 through C88.40, and C94.32 through C94.80 represent specific coding gaps in the ICD-10-CM structure — those are where the classification system has breaks between malignancy categories. If your code falls in a gap, verify the correct code before submitting.
Aetna Dendritic Cell Immunotherapy Exclusions and Non-Covered Indications
The policy summary does not specify explicit experimental or investigational designations within this modification. However, dendritic cell immunotherapy has historically carried "experimental/investigational" status under Aetna for many indications.
The real issue here is context. CPB 0377 applies to the full range of malignancies, but Aetna's coverage policy for dendritic cell immunotherapy overall has been restrictive. Reimbursement for this therapy isn't guaranteed just because a diagnosis code lands in the covered ICD-10 range.
If you're billing for dendritic cell immunotherapy for a diagnosis not clearly within C00.0–C96.9 or D03.0–D03.9, expect denial. And if you're billing for a covered diagnosis but the specific immunotherapy approach isn't aligned with what Aetna considers medically necessary, you'll get a denial on that basis too. Talk to your compliance officer before submitting claims for any indications you're unsure about.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Malignant neoplasms — leukemia, lymphoma, solid tumors | Covered when criteria met | C00.0–C43.9, C44.00–C75.9, C76.0–C86.61, C88.40–C94.32, C94.80–C96.4 | Medical necessity documentation required; confirm prior auth by plan |
| Hematologic malignancies (specified) | Covered when criteria met | C96.6, C96.7, C96.8, C96.9 | Specific malignancy code required — unspecified codes carry denial risk |
| Melanoma in situ | Covered when criteria met | D03.0–D03.9 | All anatomical sites included; confirm plan-level coverage |
| Malignancies outside covered ICD-10 ranges | Not covered | — | Claims will deny; verify diagnosis coding before submitting |
Aetna Dendritic Cell Immunotherapy Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit your ICD-10-CM coding against the updated covered ranges before September 26, 2025 claims are resubmitted. The effective date is September 26, 2025. Any claims submitted after that date need to reflect the current CPB 0377 diagnosis code requirements. Pull any pending Aetna claims for dendritic cell immunotherapy and verify the diagnosis code maps to C00.0–C96.9 or D03.0–D03.9. |
| 2 | Verify prior authorization status at the plan level — not just the policy level. CPB 0377 sets the coverage policy framework. Individual Aetna plans layer their own prior auth requirements on top. Call Aetna's provider line and confirm prior auth requirements for each patient's specific plan before treatment. |
| 3 | Don't use unspecified malignancy codes when specific ones are available. C96.9 (hematologic malignancy, unspecified) is covered, but using it when a more specific code exists invites both medical necessity denials and audit scrutiny. Code to the highest level of specificity your clinical documentation supports. |
| 4 | Flag melanoma in situ claims (D03.0–D03.9) for secondary review. Melanoma in situ sits in different territory than invasive melanoma. Make sure your documentation clearly supports the specific site code — D03.0 through D03.9 cover different anatomical sites, and the wrong site code creates unnecessary claim denial risk. |
| 5 | Check for ICD-10-CM coding gaps in the C-code ranges. The covered ranges aren't continuous. The policy lists specific range segments: C00.0–C43.9, C44.00–C75.9, C76.0–C86.61, C88.40–C94.32, and C94.80–C96.4, plus individual codes C96.6, C96.7, C96.8, and C96.9. A code that falls between listed ranges may not be covered. Build a reference list for your charge capture team. |
| 6 | Update your charge capture and billing guidelines documents to reflect the September 26, 2025 effective date. Your internal billing guidelines should note when this version of CPB 0377 took effect. If you ever face a coverage dispute or appeal, the effective date matters for which version of the policy applies. |
| 7 | If your patient volume includes significant oncology billing, loop in your compliance officer. Dendritic cell immunotherapy billing sits in a complicated space — high clinical stakes, historically restrictive coverage, and broad diagnosis code ranges that can create false confidence. Your compliance officer should review your documentation protocols before the effective date. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Dendritic Cell Immunotherapy Under CPB 0377
The policy data for CPB 0377 does not list specific CPT or HCPCS procedure codes. This is worth noting in practical terms: the absence of specific procedure codes in the policy data means your team needs to verify which codes Aetna maps to dendritic cell immunotherapy billing through the provider portal or by direct payer inquiry. Don't assume a procedure code is covered simply because the diagnosis code matches — confirm the full claim combination.
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| C00.0–C43.9 | Malignant neoplasms — leukemia, lymphoma, melanoma, solid tumors |
| C44.00–C75.9 | Malignant neoplasms — leukemia, lymphoma, melanoma, solid tumors |
| C76.0–C86.61 | Malignant neoplasms — leukemia, lymphoma, melanoma, solid tumors |
| C88.40–C94.32 | Malignant neoplasms — leukemia, lymphoma, melanoma, solid tumors |
| C94.80–C96.4 | Malignant neoplasms — leukemia, lymphoma, melanoma, solid tumors |
| C96.6 | Malignant neoplasm (hematologic malignancy — specified) |
| C96.7 | Malignant neoplasm (hematologic malignancy — specified) |
| C96.8 | Malignant neoplasm (hematologic malignancy — specified) |
| C96.9 | Malignant neoplasm, hematologic, unspecified |
| D03.0 | Melanoma in situ — unspecified site |
| D03.1 | Melanoma in situ — eyelid including canthus |
| D03.2 | Melanoma in situ — ear and external auricular canal |
| D03.3 | Melanoma in situ — other and unspecified parts of face |
| D03.4 | Melanoma in situ — scalp and neck |
| D03.5 | Melanoma in situ — trunk |
| D03.6 | Melanoma in situ — upper limb including shoulder |
| D03.7 | Melanoma in situ — lower limb including hip |
| D03.8 | Melanoma in situ — other sites |
| D03.9 | Melanoma in situ — site unspecified |
The D03 codes deserve specific attention from dermatology and surgical oncology billing teams. All nine anatomical site variants are included. The distinction between D03.8 (other sites) and D03.9 (site unspecified) matters — use D03.9 only when the clinical documentation genuinely doesn't specify a site. Using an unspecified code when the site is documented creates audit exposure.
For the C-code ranges, your coders should build a quick reference that clearly marks the covered segments. The gaps between C43.9 and C44.00, between C75.9 and C76.0, between C86.61 and C88.40, and between C94.32 and C94.80 reflect ICD-10-CM structural breaks — but they still create confusion in charge capture workflows. A simple one-page reference sheet prevents costly miscoding.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.